

Candesartan is associated with myalgia and is metabolised by the same cytochrome P450 isoenzyme 3A4 as Donepezil, which led us to suspect Donepezil of potentiating the adverse effect of Candesartan. However, at this stage, it remains a hypothesis.

Key points

- Donepezil needs to be used with care; and pain as an adverse effect needs to be considered.
- Further research into interactions between Candesartan and Donepezil and the role of cytochrome P450 isoenzyme 3A4 is warranted.

Conflicts of interest

None.

Source of funding

None.

References

1. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. *Eur Neuropsychopharmacol* 2000; 10: 195–203.
2. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. *Int J Clin Pract Suppl* 2002; 127: 45–63.
3. Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, Oremus M. Drug treatments for Alzheimer's disease. I. A comparative analysis of clinical trials. Ottawa: Canadian Coordinating Office of Health Technology Assessment (CCOHTA), 2000.
4. Rogers SL, Friedhoff LT, Apter JT, Richter RW, Hartford JT, Walshe TM, *et al*: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. *Dementia* 1996; 7: 293–303.
5. Aricept prescribing information [home page on the internet]. USA: Eisai and Pfizer; c 2005 [about 23 screens]. http://www.aricept.com/pi/aricept_pi.htm (revised March 2005).

Received 13 January 2006; accepted in revised form 8 June 2006

Age and Ageing 2006; **35**: 640–641 © The Author 2006. Published by Oxford University Press on behalf of the British Geriatrics Society. doi:10.1093/ageing/afl096 All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Published electronically 30 August 2006

It was not just a heatwave! Neuroleptic malignant-like syndrome in a patient with Parkinson's disease

AVION DOUGLAS, JACKIE MORRIS

Royal Free Hospital NHS Trust, Pond Street, London NW3, UK

Address correspondence to: A. Douglas. Email: aviondouglas@yahoo.com

Abstract

Neuroleptic malignant-like syndrome (NMLS) is a rare but life threatening and important complication because of the withdrawal of long-term L-Dopa therapy in Parkinson's disease patients. In this case report, we review the pathophysiology, clinical features and treatment of this curable condition.

Keywords: *neuroleptic malignant-like syndrome, Parkinson's disease, apomorphine, elderly*

Case report

A 76-year-old woman with advanced idiopathic Parkinson's disease was admitted to hospital with aspiration pneumonia. She was treated with intravenous antibiotics and all regular medications including L-Dopa preparations were given

through a nasogastric feeding tube at the correct doses and times. Later in the admission, she experienced florid dyskinesias and painful dystonias. Consequently, total daily L-Dopa was slowly reduced from 1,250 to 875 mg, and the dopamine agonist cabergoline introduced.

One hot summer's day, she deteriorated with acute confusion, high fever (41°C), labile blood pressure and marked generalised rigidity. Blood tests confirmed leucocytosis, elevated creatinine kinase (>2,000) and acute renal impairment because of rhabdomyolysis. She was diagnosed with neuroleptic malignant-like syndrome (NMLS) and was promptly given subcutaneous apomorphine for the first 24 h, followed by nasogastric L-Dopa. She recovered within 48 h with simultaneous aggressive cooling, intravenous hydration and antibiotics.

Discussion

NMLS and neuroleptic malignant syndrome (NMS) are clinically distinct entities. NMLS is a rare but life threatening and important complication of the cessation of L-Dopa therapy. It is seen in Parkinson's patients after relative or absolute L-Dopa withdrawal. Postulated pathophysiologic mechanisms include central dopamine receptor blockade, autonomic dysfunction and skeletal muscle hypermetabolism [1]. NMS, in contrast, is the idiosyncratic reaction to antipsychotic drugs.

This patient had deliberate although appropriate and cautiously slow L-Dopa dose reduction to manage the dyskinesias. Additional unpredictable but significant dose reductions were due to poor compliance during the acute illness before admission and inadvertent missed doses due to recurrent nasogastric tube dislocations whilst an inpatient. These factors superimposed on the other recognised triggers such as hot weather, intercurrent infection, stress and general debility that precipitated the episode of NMLS in this patient [2].

An accurate, early diagnosis of NMLS relies on a high index of clinical suspicion. The mainstay of treatment is prompt oral or nasogastric L-Dopa repletion. Apomorphine is an effective and practical alternative when oral medications cannot be administered [3, 4]. Patients should be given supportive care on a high-dependency unit with aggressive cooling, fluid and electrolyte repletion and intravenous antibiotics. Other drugs with clinical efficacy include bromocriptine, dantrolene, amantadine and pulsed steroids [5, 6].

Common complications of NMLS are rhabdomyolysis, renal failure, respiratory failure, sepsis, disseminated intravascular coagulation and seizures. Mortality is 10–30%. Poor prognostic markers include older age, high Hoehn and Yahr stage, higher akinesia score and the absence of wearing off phenomenon before developing NMLS [6].

This case highlights a rare but life-threatening and important complication of the withdrawal of L-Dopa therapy. It emphasises the absolute necessity for strict compliance with L-Dopa treatment at the correct doses and correct times in all Parkinson's disease patients, especially during acute illness and hospital admissions. Early recognition of NMLS relies on a high index of clinical suspicion. Prompt

treatment with oral or nasogastric L-Dopa or subcutaneous apomorphine is life saving.

Key points

- NMLS is rare, life threatening and potentially curable.
- NMLS is seen in Parkinson's patients after relative or absolute L-Dopa depletion.
- Triggers for NMLS include poor L-Dopa compliance, poor oral intake or absorption, dose reduction, hot weather, inter-current infection, stress and general debility.
- An accurate, early diagnosis of NMLS relies on a high index of clinical suspicion.
- Prompt L-Dopa repletion or subcutaneous apomorphine and supportive therapy is curative.

Conflicts of interest

None known.

Funding

Not applicable.

References

1. Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. *J Neurol Neurosurg Psychiatry* 2001; 71: 111–3.
2. Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. *Parkinsonism Relat Disord* 2003; 9 (Suppl. 1): S3–S9.
3. Bonuccelli U, Piccini P, Corsini GU, Muratorio A. Apomorphine in malignant syndrome due to levodopa withdrawal. *Ital J Neurol Sci* 1992; 13: 169–70.
4. Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. *Clin Neuropharmacol* 1994; 17: 243–59.
5. Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. *Neural Transm Park Dis Dement Sect* 1993; 6: 63–72.
6. Sato Y, Asoh T, Metoki N, Satoh K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2003; 74: 574–6.

Received 7 March 2006; accepted in revised form 7 July 2006